Oculis Holding AG OCS

NAS: OCS | ISIN: CH1242303498 20/09/2024

12,00 USD (+0,59%)

(+0,59%) 20/09/2024

Grafiek Oculis Holding AG

Grafiek Oculis Holding AG

1 dag1d 0,59%
1 week1w 0,25%
1 maand1m 0,46%
3 maanden3m 2,56%
6 maanden6m 3,27%
1 jaar1j -1,80%
5 jaar5j 10,19%

Oculis Holding AG in het nieuws

Toon enkel gratis nieuws

27 augustus 2024 · Oculis Publishes Consolidated Q2 Financial Statements and MD&A · Persbericht

27 augustus 2024 · Oculis Reports Q2 Financial Results and Provides Recent Company Update · Persbericht

15 augustus 2024 · Oculis Appoints Sharon Klier, M.D., M.S., M.P.H. as Chief Development Officer · Persbericht

10 juni 2024 · Oculis Announces Positive Topline Results of Phase 2b RELIEF Trial with Licaminlimab, Designed to Transform the Treatment Paradigm of Dry Eye Disease with a Precision Medicine Strategy · Persbericht

4 juni 2024 · Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities · Persbericht

30 mei 2024 · Oculis Publishes Results of 2024 Annual General Meeting and Announces Appointments to its Board of Directors and Scientific Advisory Board · Persbericht

17 mei 2024 · Oculis updates share capital for its existing at-the-market offering program · Persbericht

8 mei 2024 · Oculis Reports Q1 2024 Financial Results and Provides Company Updates · Persbericht

7 mei 2024 · Oculis Publishes Invitation to the Annual General Meeting · Persbericht

22 april 2024 · Oculis Announces Closing of Registered Direct Offering and Commencement of Trading on Nasdaq Iceland Main Market · Persbericht

Profiel Oculis Holding AG

Werknemers: 28

Aandelen Oculis Holding AG

Beurswaarde: 489,69 miljoen USD

Effecten: 40,50 miljoen

Mijn selecties

Je selectie is nog leeg.

Voeg nu effecten toe